Could a protein called VISTA be the key to understanding MS?

NCT ID NCT06957145

Completed Knowledge-focused Sponsor: Koç University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study compares levels of a protein called VISTA in immune cells from people with multiple sclerosis (MS) or clinically isolated syndrome (CIS) and healthy volunteers. Researchers will take blood samples at the first attack and again at 6 and 12 months to see if VISTA levels change over time. The goal is to learn whether VISTA could serve as a biomarker or lead to new treatments for MS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could point toward VISTA as a biomarker for MS and help develop new treatments that target the immune system.
What could go wrong: This is an early observational study with only 60 participants, so results may not apply to all MS patients. It measures proteins, not direct treatment effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, MS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, MS

Contacts and locations

Locations

Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic and Neurosurgical Diseases, University of Health Sciences, Istanbul, Turkey

Istanbul, Turkey (Türkiye)
Koc University

Istanbul, Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.